PNC Financial Services Group Inc. Has $61,000 Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

PNC Financial Services Group Inc. reduced its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 69.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,227 shares of the company’s stock after selling 11,633 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Intellia Therapeutics were worth $61,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in NTLA. ARK Investment Management LLC increased its holdings in shares of Intellia Therapeutics by 2.3% during the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock valued at $146,174,000 after acquiring an additional 280,946 shares in the last quarter. State Street Corp increased its stake in Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after purchasing an additional 780,754 shares in the last quarter. Geode Capital Management LLC increased its stake in Intellia Therapeutics by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock valued at $48,164,000 after purchasing an additional 49,367 shares in the last quarter. FMR LLC raised its holdings in Intellia Therapeutics by 5.0% during the third quarter. FMR LLC now owns 2,339,522 shares of the company’s stock worth $48,077,000 after buying an additional 111,104 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its stake in shares of Intellia Therapeutics by 33.5% in the third quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company’s stock valued at $21,118,000 after buying an additional 257,700 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $8.31 on Thursday. The firm has a market cap of $860.23 million, a price-to-earnings ratio of -1.53 and a beta of 1.97. Intellia Therapeutics, Inc. has a 52 week low of $8.12 and a 52 week high of $28.23. The firm’s 50-day simple moving average is $10.03 and its two-hundred day simple moving average is $13.93.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. BMO Capital Markets decreased their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. HC Wainwright assumed coverage on Intellia Therapeutics in a report on Wednesday, March 5th. They set a “buy” rating and a $30.00 price objective for the company. Oppenheimer lowered their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $13.00 price target (down previously from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Finally, Wedbush reissued a “neutral” rating and issued a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $37.56.

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 29,000 shares of company stock worth $352,551 in the last quarter. Insiders own 3.20% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.